🇺🇸 FDA
Pipeline program

Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

BN42083

Phase 3 small_molecule active

Quick answer

Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg for Primary Progressive Multiple Sclerosis (PPMS) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Primary Progressive Multiple Sclerosis (PPMS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials